ACLX News and Press, Arcellx Inc. From 06/08/22

ACLX is a clinical-stage biotech that aims to develop potentially "safer, more effective, and more broadly accessible" CAR-T cell therapies for cancers and incurable diseases. On June 3, ACLX presented p1 data of their lead candidate, CART-ddBCMA, for relapsed or refractory multiple m...

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting PR Newswire -- 100% ORR at both dose levels; deep and durable responses ob...

Biotechnology company Arcellx (NASDAQ:ACLX) appointed Michelle Gilson CFO. Gilson joins Arcellx from Canaccord Genuity. She most recently served as managing director and senior equity research analyst covering biotechnology companies at Canaccord Genuity. For further details see: ...

Arcellx Appoints Michelle Gilson as Chief Financial Officer PR Newswire FOSTER CITY, Calif. , May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies...

The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Investor Presentation - Slideshow

Arcellx Appoints Olivia Ware to Board of Directors PR Newswire -- Replaces Lewis T. "Rusty" Williams, M.D., on Board of Directors -- FOSTER CITY, Calif. , May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagin...

Arcellx press release (NASDAQ:ACLX): Q1 GAAP EPS of -$1.56 misses by $0.46. As of March 31, 2022, Arcellx had cash, cash equivalents, and marketable securities of $210.9 million, which is anticipated to fund its operations into the second half of 2023. For further details see: Arcellx G...

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results PR Newswire -- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) -...

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire -- ARC-SparX is a...

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire 100% ORR ; 75% CR/sCR; and evidence of durable clinical benefit ...